Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29123324 | 1.00 | LTA4H (0.54) | LTA4HSCN9AKCNH2MAPK1CDK2 | |
| SCHEMBL30006916 | 0.89 | MAPK1 (0.51) | LTA4HSCN9AMAPK1CDK2AKT1 | |
| SCHEMBL27204647 | 0.89 | LTA4H (0.67) | LTA4HSCN9AKCNH2CDK2AKT1 | |
| SCHEMBL27171402 | 0.89 | LTA4H (0.67) | LTA4HSCN9AKCNH2CDK2AKT1 | |
| SCHEMBL29123473 | 0.86 | SCN9A (0.46) | LTA4HSCN9AMAPK1FFAR1GAA | |
| SCHEMBL29123469 | 0.86 | SCN9A (0.46) | LTA4HSCN9AMAPK1FFAR1GAA | |
| SCHEMBL24665357 | 0.86 | LTA4H (0.58) | LTA4HKCNH2MAPK1FFAR1MAPT | |
| SCHEMBL27204649 | 0.86 | LTA4H (0.58) | LTA4HKCNH2MAPK1FFAR1MAPT | |
| SCHEMBL24665376 | 0.85 | LTA4H (0.56) | LTA4HSCN9AKCNH2MAPK1CDK2 | |
| SCHEMBL29123411 | 0.85 | LTA4H (0.56) | LTA4HSCN9AKCNH2MAPK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4323062-B1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2025-07-23 | — | — | EP | claimed |
| EP-4323062-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | Novartis AG (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-117015537-A | Heteroaryl aminopropanol derivatives as inhibitors of LTA4H | 诺华股份有限公司 | 2023-11-07 | — | — | CN | claimed |
| WO-2022219546-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | claimed |
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| EP-4323062-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-117015537-A | Heteroaryl aminopropanol derivatives as inhibitors of LTA4H | 诺华股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| WO-2022219546-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022219546-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | CYP3A43, CYP11B2, ADRB3 | LTA4H 1006/4885SCN9A 1338/4885KCNH2 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.